Comparative efficacy of eptifibatide and abciximab in primary angioplasty study
نویسندگان
چکیده
منابع مشابه
Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
OBJECTIVES The aim of this study was to test the noninferiority of eptifibatide relative to abciximab in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). BACKGROUND Glycoprotein IIb/IIIa inhibitors are recommended by international guidelines in patients with acute coronary syndromes undergoing PCI. Abciximab is rec...
متن کاملRandomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
OBJECTIVES The aim of this study was to compare eptifibatide and abciximab as adjuncts to primary percutaneous coronary intervention (PCI). BACKGROUND The glycoprotein (GP) IIb/IIIa receptor inhibitor abciximab as adjunct to primary PCI in patients with ST-segment elevation myocardial infarctions has been shown to reduce ischemic complications and improve clinical outcomes. So far, no trial h...
متن کاملComparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction
BACKGROUND Administration of glycoprotein IIb/IIIa inhibitors is an effective adjunctive treatment strategy during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI). Recent data suggest that an intracoronary administration of these drugs can increase the efficacy of PPCI. This study was done to find any potential difference in terms of effi...
متن کاملThe safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide.
n this issue of the Journal, Gurm et al. (1) present bservational data showing no apparent difference in early utcome among primary percutaneous coronary intervenion (PCI) patients receiving the small-molecule platelet lycoprotein (GP) IIb/IIIa inhibitor eptifibatide versus hose receiving the monoclonal antibody abciximab. Their ndings are from the Blue Cross Blue Shield of Michigan ardiovascul...
متن کاملThe TARGET trial: hit or miss?
Over the past 8 years large-scale, placebo-controlled trials have established the efficacy of intravenous platelet glycoprotein (GP) IIb/IIIa inhibitors at reducing the 30-day composite of death, myocardial infarction, and urgent target vessel revascularization associated with percutaneous coronary angioplasty, atherectomy, and stent placement. Using abciximab, tirofiban, or eptifibatide, each ...
متن کامل